表柔比星膀胱灌注化疗预防膀胱癌术后复发62例临床研究  

Clinical Study on Epirubicin Instillation Chemotherapy in Preventing 62 Recurrent Cases after the Bladder Cancer

作　　者：陈慧忠 蔡法亮 CHEN Hui-zhong;CAI Fa-liang(Department of Urinary Surgery,Dongshan Hospital,Dongshan,Fujian Province,363400 China)

机构地区：[1]东山县医院泌尿外科,福建东山363400

出　　处：《中外医疗》2018年第36期129-131,共3页China & Foreign Medical Treatment

摘　　要：目的研究与分析表柔比星膀胱灌注化疗预防膀胱癌术后复发的临床疗效。方法方便选取2014年1月—2016年11月期间该院膀胱癌术后进行膀胱灌注化疗的124例膀胱癌患者为研究对象,将其根据治疗方式的不同分为对照组(丝裂霉素组)62例和观察组(表柔比星组)62例。比较两组患者术后不同时间的复发率、不良反应发生率及治疗前后的生存质量评分。结果观察组术后<12个月、12～18个月及19～24个月的复发率分别为0.00%、1.61%、1.61%及3.23%,均低于对照组的6.45%、11.29%、11.29%及29.03%(χ~2=4.133,4.810,4.810,15.262,P<0.05),两组的不良反应发生率比较,差异无统计学意义(P>0.05),观察组治疗后1个月及6个月的生存质量评分分别为(36.24±3.68)分、(41.38±4.96)分、(43.06±5.11)分、(47.82±4.88)分及(42.56±4.26)分、(53.65±5.49)分、(53.02±5.87)分、(53.22±5.67)分,均高于对照组的(31.98±3.40)分、(38.98±4.68)分、(40.38±5.02)分、(43.98±4.64)分及(40.25±3.94)分、(51.32±5.16)分、(50.86±5.52)分、(50.42±5.10)分(t=6.694,2.771,2.945,4.490,3.134,2.435,2.110,2.890,P<0.05)。结论表柔比星膀胱灌注化疗预防膀胱癌术后复发的临床疗效较好,安全性也值得肯定,在膀胱癌术后的应用价值更高。Objective To investigate the clinical curative effect of epirubicin instillation chemotherapy in preventing the recurrent cases after the bladder cancer.Methods 124 cases of patients with bladder cancer for bladder perfusion chemotherapy after the bladder cancer surgery in our hospital from January 2014 to November 2016 were selected as the research objects and divided into two groups with 62 cases in each according to different treatment ways,including the control group(mitomycin group)and the observation group(epirubicin group),and the recurrence rates at different time,incidence rate of adverse reactions and survival quality scores before treatment were compared between groups.Results The recurrence rates in the postoperative﹤12 months,12-18 months and 19-24 months in the observation group were lower than those in the control group[0.00%,1.61%,1.61%,3.23%vs 6.45%,11.29%,11.29%,29.03%(χ^2=4.133,4.810,4.810,15.262,P﹤0.05)],and the difference in the incidence rate of adverse reactions between the two groups was not statistically significant(P >0.05),and the survival quality scores in 1 month and 6 months after treatment in the observation group were higher than those in the control group[(36.24±3.68)points,(41.38±4.96)points,(43.06±5.11)points,(47.82±4.88)points,(42.56±4.26)points,(53.65±5.49)points,(53.02±5.87)points,(53.22±5.67)points vs(31.98±3.40)points,(38.98±4.68)points,(40.38±5.02)points,(43.98±4.64)points,(40.25±3.94)points,(51.32±5.16)points,(50.86±5.52)points,(50.42±5.10)points(t=6.694,2.771,2.945,4.490,3.134,2.435,2.110,2.890,P﹤0.05)].Conclusion The clinical curative effect of epirubicin instillation chemotherapy in preventing the recurrent cases after the bladder cancer is better,and the safety is worth recognition,and it is of higher application value after the bladder surgery.

关 键 词：表柔比星 膀胱灌注化疗 膀胱癌 术后复发 

分 类 号：R737[医药卫生—肿瘤]